{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:07:29Z","timestamp":1794049649393,"version":"4.8.0"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100024845","name":"Institute of Theoretical and Experimental Biophysics RAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024845","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.neuroscience.2026.03.023","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:42:54Z","timestamp":1773942174000},"page":"37-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cannabinoids and cognition in Parkinson\u2019s disease: Insights from animal models and emerging clinical evidence"],"prefix":"10.1016","volume":"603","author":[{"given":"Valentina F.","family":"Kitchigina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6781-5779","authenticated-orcid":false,"given":"Liubov","family":"Shubina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2026.03.023_b0005","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/WNL.56.6.730","article-title":"Risk of dementia in Parkinson\u2019s disease","volume":"56","author":"Aarsland","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbr.2015.04.002","article-title":"Ventral tegmental area cholinergic mechanisms mediate behavioral responses in the forced swim test","volume":"288","author":"Addy","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.baga.2015.06.001","article-title":"The vulnerable ventral tegmental area in Parkinson\u2019s disease","volume":"5","author":"Alberico","year":"2015","journal-title":"Basal Ganglia"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0301-0082(02)00080-1","article-title":"Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids","volume":"68","author":"Alger","year":"2002","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2016.00019","article-title":"Cannabis sativa: the plant of the thousand and one molecules","volume":"7","author":"Andre","year":"2016","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00697388","article-title":"Loss of neurons in the nucleus basalis of Meynert in Alzheimer\u2019s disease, paralysis agitans and Korsakoff\u2019s disease","volume":"61","author":"Arendt","year":"1983","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133002","article-title":"Sex differences in clinical features of early, treated Parkinson\u2019s disease","volume":"10","author":"Augustine","year":"2015","journal-title":"Plos One"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bcp.2018.08.016","article-title":"Cannabinoid pharmacology\/therapeutics in chronic degenerative disorders affecting the central nervous system","volume":"157","author":"Aymerich","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0045","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3390\/biom14101296","article-title":"Unveiling the potential of phytocannabinoids: exploring marijuana\u2019s lesser-known constituents for neurological disorders","volume":"14","author":"Basavarajappa","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0050","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1523\/JNEUROSCI.20-09-03401.2000","article-title":"Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor","volume":"20","author":"Beltramo","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0055","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjp.0707505","article-title":"Cannabinoid CB2 receptors in human brain inflammation","volume":"153","author":"Benito","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0060","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/glia.24172","article-title":"Endocannabinoid signaling in brain diseases: emerging relevance of glial cells","volume":"71","author":"Bernal-Chico","year":"2023","journal-title":"Glia"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0065","first-page":"141","article-title":"Limbic neuropathology in idiopathic Parkinson\u2019s disease with concomitant dementia","volume":"42","author":"Bertrand","year":"2004","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fcogn.2024.1379896","article-title":"Genetic background of cognitive decline in Parkinson\u2019s disease","volume":"3","author":"Blazekovic","year":"2024","journal-title":"Front. Cognit."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0075","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2018.10.006","article-title":"The neuropsychopharmacology of cannabis: a review of human imaging studies","volume":"195","author":"Bloomfield","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0080","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1001\/archneur.60.12.1745","article-title":"Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer disease","volume":"60","author":"Bohnen","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0085","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1007\/s00213-015-3915-0","article-title":"Further human evidence for striatal dopamine release induced by administration of \u03949-tetrahydrocannabinol (THC): selectivity to limbic striatum","volume":"232","author":"Bossong","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.31083\/j.jin2312221","article-title":"Coherent changes in neural motor network activity during levodopa-induced dyskinesia in a rat model of Parkinson\u2019s disease","volume":"23","author":"Brazhnik","year":"2024","journal-title":"J. Integr. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0100","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1471-4892(02)00011-5","article-title":"CB1 cannabinoid receptor signalling in Parkinson\u2019s disease","volume":"3","author":"Brotchie","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0105","doi-asserted-by":"crossref","first-page":"9800","DOI":"10.1073\/pnas.0703472104","article-title":"[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor","volume":"104","author":"Burns","year":"2007","journal-title":"PNAS"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0110","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fphar.2017.00269","article-title":"Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders","volume":"8","author":"Campos","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.phrs.2016.01.033","article-title":"Cannabidiol, neuroprotection and neuropsychiatric disorders","volume":"112","author":"Campos","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0120","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","article-title":"Cannabis for dyskinesia in Parkinson disease","volume":"63","author":"Carroll","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0125","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JPD-191683","article-title":"Parkinson\u2019s disease in women and men: what\u2019s the difference?","volume":"9","author":"Cerri","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/jcpt.12179","article-title":"Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson\u2019s disease patients: a case series","volume":"39","author":"Chagas","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0135","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881114550355","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial","volume":"28","author":"Chagas","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0140","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1007\/s00415-024-12374-5","article-title":"GBA moderates cognitive reserve\u2019s effect on cognitive function in patients with Parkinson\u2019s disease","volume":"271","author":"Chang","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0145","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0006-8993(93)90298-2","article-title":"Ventral tegmental microinjection of \u03949-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana\u2019s psychoactive ingredient","volume":"621","author":"Chen","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0155","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0896-6273(03)00235-6","article-title":"Heterosynaptic LTD of hippocampal GABAergic synapses","volume":"38","author":"Chevaleyre","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0160","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jpsychires.2025.10.069","article-title":"The role of motor subtypes in modulating neuropsychiatric and cognitive function in Parkinson\u2019s disease: a group-stratified mediation analysis","volume":"192","author":"Chien","year":"2026","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0165","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3758\/s13415-025-01343-8","article-title":"Cognitive function in different motor subtypes of Parkinson\u2019s disease: a systematic review and multilevel meta-analysis","volume":"26","author":"Child","year":"2026","journal-title":"Cogn. Affect. Behav. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.parkreldis.2018.02.007","article-title":"Sex differences in progression to mild cognitive impairment and dementia in Parkinson\u2019s disease","volume":"50","author":"Cholerton","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0175","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.4049\/jimmunol.1102435","article-title":"Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation","volume":"187","author":"Chung","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0180","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1006\/nbdi.1998.0220","article-title":"Brain cannabinoid systems as targets for the therapy of neurological disorders","volume":"5","author":"Consroe","year":"1998","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/npp.2017.140","article-title":"Sex-dependent effects of cannabis and cannabinoids: a translational perspective","volume":"43","author":"Cooper","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0190","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/brainsci12121596","article-title":"Cannabinoids in late life Parkinson\u2019s disease and dementia: biological pathways and clinical challenges","volume":"12","author":"Costa","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0195","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0200","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/add.15764","article-title":"Evidence on the acute and residual neurocognitive effects of cannabis use in adolescents and adults: a systematic meta\u2010review of meta\u2010analyses","volume":"117","author":"Dellazizzo","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0205","doi-asserted-by":"crossref","unstructured":"Devane, W.A., Hanu\u0161, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R., 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1979). 258, 1946\u20131949. Doi: 10.1126\/science.1470919.","DOI":"10.1126\/science.1470919"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0210","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrd.2018.115","article-title":"New approaches and challenges to targeting the endocannabinoid system","volume":"17","author":"Di Marzo","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0215","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1046\/j.1471-4159.2000.0752434.x","article-title":"Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain","volume":"75","author":"Di Marzo","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0220","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1096\/fasebj.14.10.1432","article-title":"Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson\u2019s disease","volume":"14","author":"Di Marzo","year":"2000","journal-title":"FASEB J."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0225","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/mds.29447","article-title":"Cognitive safety data from a randomized, double-blind, parallel-group, placebo-controlled phase IIb study of the effects of a cannabidiol and \u03949-tetrahydrocannabinol drug on Parkinson\u2019s disease-related motor symptoms","volume":"38","author":"Domen","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0230","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028668","article-title":"Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement","volume":"6","author":"Esposito","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0240","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jalz.2014.06.016","article-title":"Influence of microglial activation on neuronal function in Alzheimer\u2019s and Parkinson\u2019s disease dementia","volume":"11","author":"Fan","year":"2015","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0245","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1054\/plef.2001.0350","article-title":"Endocannabinoids and basal ganglia functionality","volume":"66","author":"Fern\u00e1ndez-Ruiz","year":"2002","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids (PLEFA)"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0250","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.neurobiolaging.2014.05.021","article-title":"The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model","volume":"35","author":"Fern\u00e1ndez-Su\u00e1rez","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0255","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.neuro.30.051606.094341","article-title":"Ventral tegmental area neurons in learned appetitive behavior and positive reinforcement","volume":"30","author":"Fields","year":"2007","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0260","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","article-title":"Medical, surgical, and physical treatments for Parkinson\u2019s disease","volume":"403","author":"Foltynie","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0265","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1152\/physrev.00004.2003","article-title":"Role of endogenous cannabinoids in synaptic signaling","volume":"83","author":"Freund","year":"2003","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0270","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/ja01062a046","article-title":"Isolation, structure, and partial synthesis of an active constituent of hashish","volume":"86","author":"Gaoni","year":"1964","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0275","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson\u2019s disease: importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Garc\u00eda-Arencibia","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0280","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/7268","article-title":"Dopamine activation of endogenous cannabinoid signaling in dorsal striatum","volume":"2","author":"Giuffrida","year":"1999","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105406","article-title":"Long-term safety of medical cannabis in Parkinson\u2019s disease: a retrospective case-control study","volume":"112","author":"Goldberg","year":"2023","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0290","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cger.2020.01.001","article-title":"Cognitive impairment and dementia in Parkinson disease","volume":"36","author":"Goldman","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0295","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.brainres.2005.04.010","article-title":"Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice","volume":"1046","author":"Gonz\u00e1lez","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0300","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002","article-title":"Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission","volume":"22","author":"Gubellini","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0305","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1007\/s11064-023-03899-8","article-title":"The effects of chronic marijuana administration on 6-OHDA-induced learning & memory impairment and hippocampal dopamine and cannabinoid receptors interaction in male Rats","volume":"48","author":"Haghparast","year":"2023","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0310","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pneurobio.2004.05.002","article-title":"Genes, proteins, and neurotoxins involved in Parkinson\u2019s disease","volume":"73","author":"von Halbach","year":"2004","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0315","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","article-title":"Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study","volume":"11","author":"Herkenham","year":"1991","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0320","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0306-4522(01)00509-7","article-title":"Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain","volume":"109","author":"Hermann","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0325","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/mdc3.13414","article-title":"Higher risk, higher reward? Self\u2010reported effects of real\u2010world cannabis use in Parkinson\u2019s disease","volume":"9","author":"Holden","year":"2022","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0330","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/exnr.2000.7483","article-title":"Reduced BDNF mRNA expression in the Parkinson\u2019s disease substantia nigra","volume":"166","author":"Howells","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0335","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2174\/1570159X21666221121094343","article-title":"Surgical advances in Parkinson\u2019s disease","volume":"22","author":"Hvingelby","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0340","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of cannabidiol in neurological disorders","volume":"12","author":"Ibeas Bih","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0345","doi-asserted-by":"crossref","unstructured":"Jellinger, K.A., 1999. Post mortem studies in Parkinson\u2019s disease \u2014 is it possible to detect brain areas for specific symptoms? pp. 1\u201329. Doi: 10.1007\/978-3-7091-6360-3_1.","DOI":"10.1007\/978-3-7091-6360-3_1"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0350","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF03159935","article-title":"Pathology of Parkinson\u2019s disease","volume":"14","author":"Jellinger","year":"1991","journal-title":"Mol. Chem. Neuropathol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0355","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0306-4522(03)00070-8","article-title":"Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia","volume":"119","author":"Julian","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0360","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","article-title":"Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors","volume":"372","author":"Kathmann","year":"2006","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0365","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.3390\/ijms25158520","article-title":"Therapeutic application of modulators of endogenous cannabinoid system in Parkinson\u2019s disease","volume":"25","author":"Khaspekov","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0370","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s11055-021-01148-5","article-title":"Cannabinoids, the endocannabinoid system, and cognitive functions: enemies or friends?","volume":"51","author":"Kitchigina","year":"2021","journal-title":"Neurosci. Behav. Physiol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0375","unstructured":"Kitchigina, V.F., 2016. [Endogenous cannabinoid system of the brain as the target for influences at neurodegenerate diseases]. Zh. Vyssh. Nerv. Deiat. Im. I P Pavlova 66, 387\u2013413."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0380","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/ana.25236","article-title":"Serotonin, \u03b2\u2010amyloid, and cognition in Parkinson disease","volume":"83","author":"Kotagal","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0385","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00401-003-0705-2","article-title":"Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson\u2019s disease","volume":"106","author":"K\u00f6vari","year":"2003","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0390","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.1523\/JNEUROSCI.2959-05.2005","article-title":"Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum","volume":"25","author":"Kreitzer","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0395","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/pharmaceutics16040514","article-title":"Assessing the safety and therapeutic efficacy of cannabidiol lipid nanoparticles in alleviating metabolic and memory impairments and hippocampal histopathological changes in diabetic Parkinson\u2019s rats","volume":"16","author":"Lapmanee","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0400","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0405","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1046\/j.0953-816x.2001.01812.x","article-title":"Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson\u2019s syndrome and of MPTP-treated marmosets","volume":"14","author":"Lastres-Becker","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0410","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","article-title":"Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson\u2019s disease","volume":"19","author":"Lastres-Becker","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0415","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","article-title":"Parkinson\u2019s disease","volume":"373","author":"Lees","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0420","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.neuron.2015.09.024","article-title":"Disinhibition, a circuit mechanism for associative learning and memory","volume":"88","author":"Letzkus","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0425","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/acn3.299","article-title":"Plasma EGF and cognitive decline in Parkinson\u2019s disease and Alzheimer\u2019s disease","volume":"3","author":"Lim","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0430","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00482","article-title":"Cognitive profiles and hub vulnerability in Parkinson\u2019s disease","volume":"9","author":"Lin","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0435","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/19336950.2021.1910461","article-title":"Potassium channels as molecular targets of endocannabinoids","volume":"15","author":"Lin","year":"2021","journal-title":"Channels"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0440","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbi.2013.07.007","article-title":"Cerebrospinal fluid inflammatory markers in Parkinson\u2019s disease \u2013 associations with depression, fatigue, and cognitive impairment","volume":"33","author":"Lindqvist","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0445","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.29768","article-title":"Short\u2010term cannabidiol with \u0394\u20109\u2010tetrahydrocannabinol in Parkinson\u2019s disease: a randomized trial","volume":"39","author":"Liu","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0450","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0455","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/j.1471-4159.1993.tb09807.x","article-title":"Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate\u2010plitamen: an in situ hybridization study","volume":"61","author":"Mailleux","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0460","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/0306-4522(92)90409-U","article-title":"Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry","volume":"48","author":"Mailleux","year":"1992","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0465","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0470","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s004019900168","article-title":"Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson\u2019s disease","volume":"100","author":"Mattila","year":"2000","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0475","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","article-title":"Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors","volume":"50","author":"Mechoulam","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0480","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","article-title":"Hashish I. The structure of cannabidiol","volume":"19","author":"Mechoulam","year":"1963","journal-title":"Tetrahedron"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0485","doi-asserted-by":"crossref","DOI":"10.3892\/etm.2018.7129","article-title":"Cholinesterase inhibitors and memantine for Parkinson\u2019s disease dementia and Lewy body dementia: a meta\u2013analysis","author":"Meng","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0490","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41582-019-0294-x","article-title":"Sex differences in movement disorders","volume":"16","author":"Meoni","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0495","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JPD-2011-11023","article-title":"MPTP mouse models of Parkinson\u2019s disease: an update","volume":"1","author":"Meredith","year":"2011","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0500","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00002826-200405000-00003","article-title":"Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease","volume":"27","author":"Mesnage","year":"2004","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.107841","article-title":"Cannabidiol and cognitive functions\/inflammatory markers in Parkinson\u2019s disease: a double-blind randomized controlled trial at Buriram Hospital (CBD-PD-BRH trial)","volume":"135","author":"Mitarnun","year":"2025","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0510","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0165-6147(00)89070-7","article-title":"NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release","volume":"16","author":"Mody","year":"1995","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0515","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1474-4422(03)00501-5","article-title":"The environment and Parkinson\u2019s disease: is the nigrostriatal system preferentially targeted by neurotoxins?","volume":"2","author":"Monte","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0520","doi-asserted-by":"crossref","unstructured":"Morales, P., Hurst, D.P., Reggio, P.H., 2017. Molecular targets of the phytocannabinoids: a complex picture. pp. 103\u2013131. Doi: 10.1007\/978-3-319-45541-9_4.","DOI":"10.1007\/978-3-319-45541-9_4"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0525","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s11055-022-01334-z","article-title":"The contribution of the external globus pallidus to basal ganglia circuit oscillatory activity in an experimental model of Parkinson\u2019s disease","volume":"52","author":"Morozova","year":"2022","journal-title":"Neurosci. Behav. Physiol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0530","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41531-023-00535-8","article-title":"Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson\u2019s disease","volume":"9","author":"M\u00fcller-Nedebock","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0535","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0540","doi-asserted-by":"crossref","DOI":"10.1515\/revneuro-2013-0004","article-title":"Prefrontal dopamine signaling and cognitive symptoms of Parkinson\u2019s disease","volume":"24","author":"Narayanan","year":"2013","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0545","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1134\/S0006297923110172","article-title":"Pathological correlates of cognitive decline in Parkinson\u2019s disease: from molecules to neural networks","volume":"88","author":"Novikov","year":"2023","journal-title":"Biochem. Mosc."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0550","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1471-4159.2009.06557.x","article-title":"The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor\u2010independent mechanism","volume":"112","author":"Oz","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0555","doi-asserted-by":"crossref","first-page":"s40","DOI":"10.1007\/s10072-006-0546-6","article-title":"Parkinson\u2019s disease and dementia","volume":"27","author":"Padovani","year":"2006","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0560","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.25864","article-title":"Non\u2010motor symptoms in Parkinson\u2019s disease are reduced by nabilone","volume":"88","author":"Peball","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0565","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/mdc3.13471","article-title":"Effects of nabilone on sleep outcomes in patients with Parkinson\u2019s disease: a post-hoc analysis of NMS-Nab study","volume":"9","author":"Peball","year":"2022","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0570","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fphar.2016.00343","article-title":"Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats","volume":"7","author":"Peres","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2025.108434","article-title":"The effects of cannabis use disorder on cognitive functions: a meta-analysis","volume":"170","author":"Pilon","year":"2025","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0580","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrn1247","article-title":"The molecular logic of endocannabinoid signalling","volume":"4","author":"Piomelli","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0585","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/ana.20462","article-title":"High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson\u2019s disease patients","volume":"57","author":"Pisani","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0590","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0595","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0024-3205(99)00618-9","article-title":"Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen","volume":"66","author":"Romero","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0600","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/cjn.2018.21","article-title":"Effects of antiparkinson medication on cognition in Parkinson\u2019s disease: a systematic review","volume":"45","author":"Roy","year":"2018","journal-title":"Can. J. Neurol. Sci.\/Journal Canadien Des Sciences Neurologiques"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0605","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2011.00064","article-title":"Sexually dimorphic effects of cannabinoid compounds on emotion and cognition","volume":"5","author":"Rubino","year":"2011","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0610","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2024.1466438","article-title":"Low doses of cannabis extract ameliorate non-motor symptoms of Parkinson\u2019s disease patients: a case series","volume":"18","author":"Ruver-Martins","year":"2025","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0615","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1152\/jn.1997.77.3.1635","article-title":"Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat","volume":"77","author":"Sa\u00f1udo-Pe\u00f1a","year":"1997","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0620","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.parkreldis.2015.09.027","article-title":"Non motor subtypes and Parkinson\u2019s disease","volume":"22","author":"Sauerbier","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0625","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.bjp.0706328","article-title":"Dopaminergic neurones: much more than dopamine?","volume":"146","author":"Seutin","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0630","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110367","article-title":"PPAR\u03b3 receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice","volume":"111","author":"Sonego","year":"2021","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0640","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bbi.2018.09.014","article-title":"Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPAR\u03b3 receptors","volume":"74","author":"Sonego","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0645","doi-asserted-by":"crossref","unstructured":"Sousa, A., DiFrancisco-Donoghue, J., 2023. Cannabidiol and tetrahydrocannabinol use in Parkinson\u2019s disease: an observational pilot study. Cureus 24;15(7):e42391. Doi: 10.7759\/cureus.42391.","DOI":"10.7759\/cureus.42391"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0650","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/bbrc.1995.2437","article-title":"2-arachidonoylgylcerol: a possible endogenous cannabinoid receptor ligand in brain","volume":"215","author":"Sugiura","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0655","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1474-4422(12)70152-7","article-title":"Cognitive impairment in patients with Parkinson\u2019s disease: diagnosis, biomarkers, and treatment","volume":"11","author":"Svenningsson","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0660","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.parkreldis.2013.09.025","article-title":"The influence of age and gender on motor and non-motor features of early Parkinson\u2019s disease: initial findings from the oxford Parkinson disease center (OPDC) discovery cohort","volume":"20","author":"Szewczyk-Krolikowski","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0665","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0670","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0006-8993(88)90749-4","article-title":"The effects of \u03949-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study","volume":"451","author":"Ton","year":"1988","journal-title":"Brain Res."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0675","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41531-020-0110-8","article-title":"Genetic predispositions of Parkinson\u2019s disease revealed in patient-derived brain cells","volume":"6","author":"Tran","year":"2020","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0680","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0306-4522(97)00436-3","article-title":"Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system","volume":"83","author":"Tsou","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0685","doi-asserted-by":"crossref","unstructured":"Ugrumov, M.V., 2015. Development of preclinical diagnosis and preventive treatment of neurodegenerative diseases. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 115, 4. Doi: 10.17116\/jnevro20151151114-14.","DOI":"10.17116\/jnevro20151151114-14"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0690","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3233\/JPD-212923","article-title":"Effects of cannabis in Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"12","author":"Urbi","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0695","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2003.08.101","article-title":"The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders","volume":"480","author":"van der Stelt","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0700","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1096\/fj.04-3010fje","article-title":"A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson\u2019s disease","volume":"19","author":"van der Stelt","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0705","doi-asserted-by":"crossref","first-page":"620.e1","DOI":"10.1016\/j.neurobiolaging.2011.02.009","article-title":"Regional changes in type 1 cannabinoid receptor availability in Parkinson\u2019s disease in vivo","volume":"33","author":"Van Laere","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0710","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1089\/can.2023.0023","article-title":"Cannabinoids in treating Parkinson\u2019s disease symptoms: a systematic review of clinical studies","volume":"8","author":"Varshney","year":"2023","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0715","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.neuroscience.2022.06.036","article-title":"Cannabidiol alleviates the damage to dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson\u2019s disease mice via regulating neuronal apoptosis and neuroinflammation","volume":"498","author":"Wang","year":"2022","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0720","doi-asserted-by":"crossref","unstructured":"Weber, M.A., Sivakumar, K., Bova, A.S., Tabakovic, E.E., Conlon, M.M., Oya, M., Cole, R.C., Espinoza, A.I., Kim, Y., Narayanan, N.S., 2025. Ventral tegmental area dopamine controls timing variability. Doi: 10.1101\/2025.10.27.684913.","DOI":"10.1101\/2025.10.27.684913"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0725","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbr.2018.03.011","article-title":"Abnormal ventral tegmental area-anterior cingulate cortex connectivity in Parkinson\u2019s disease with depression","volume":"347","author":"Wei","year":"2018","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0730","doi-asserted-by":"crossref","unstructured":"Wilson, R.I., Nicoll, R.A., 2002. Endocannabinoid signaling in the brain. Science (1979). 296, 678\u2013682. Doi: 10.1126\/science.1063545.","DOI":"10.1126\/science.1063545"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0735","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrn1406","article-title":"Dopamine, learning and motivation","volume":"5","author":"Wise","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0740","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/00023210-200519090-00001","article-title":"Treatment of Parkinson\u2019s disease: what\u2019s on the horizon?","volume":"19","author":"Wu","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2025.111222","article-title":"Genetic and neurochemical profiles underlying cortical morphometric vulnerability to Parkinson\u2019s disease","volume":"221","author":"Yan","year":"2025","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.125703","article-title":"Global, regional and national burden of Parkinson\u2019s disease, 1990\u20132021: update from the GBD 2021 study","volume":"480","author":"Yang","year":"2026","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0755","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0306-4522(03)00607-9","article-title":"Retrograde signaling changes the venue of postsynaptic inhibition in rat substantia nigra","volume":"122","author":"Yanovsky","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0760","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neurobiolaging.2023.07.011","article-title":"Clinical and neurochemical correlates of the APOE genotype in early-stage Parkinson\u2019s disease","volume":"131","author":"Zenuni","year":"2023","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0765","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s13311-020-00963-x","article-title":"Approach to cognitive impairment in Parkinson\u2019s disease","volume":"17","author":"Zhang","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0770","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1809","article-title":"APOE4 exacerbates \u03b1-synuclein pathology and related toxicity independent of amyloid","volume":"12","author":"Zhao","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0775","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2025.1620172","article-title":"Association of brain-derived neurotrophic factor in blood and cerebrospinal fluid with Parkinson\u2019s disease and non-motor symptoms of Parkinson\u2019s disease: a systematic review and meta-analysis of 6655 participants","volume":"17","author":"Zhao","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.023_b0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.110063","article-title":"Acute effects of partial CB1 receptor agonists on cognition \u2013 a meta-analysis of human studies","volume":"104","author":"Zhornitsky","year":"2021","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2026.03.023_b0785","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease","volume":"23","author":"Zuardi","year":"2009","journal-title":"J. Psychopharmacol."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226001971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226001971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:46:23Z","timestamp":1793598383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452226001971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":157,"alternative-id":["S0306452226001971"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.03.023","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoids and cognition in Parkinson\u2019s disease: Insights from animal models and emerging clinical evidence","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}